The 2026 Nobel Prize in Physiology or Medicine has been jointly awarded to Karl Deisseroth, Peter Hegemann, and Georg Nagel for their groundbreaking discoveries related to light-gated ion channels and optogenetics — a revolutionary technique that has fundamentally transformed neuroscience. The Nobel Assembly at Karolinska Institutet in Stockholm announced the prize on Monday, 5 October 2026.

What Is Optogenetics

Optogenetics is a method that enables scientists to switch individual nerve cells in a living brain on or off using light alone. Understanding how the brain encodes memories, emotions, and behaviours has been a central ambition of neuroscience for generations — and optogenetics has made that ambition actionable in ways previously unimaginable.

Per Svenningsson, Chair of the Nobel Committee for Physiology or Medicine, described the scale of the achievement: 'Optogenetics provides opportunities for mapping the brain in a way that we could once only dream of.'

How the Discovery Was Made

The foundation was laid when Hegemann and Nagel identified channelrhodopsin, a protein with a uniquely versatile property: any cell into which the protein was introduced became sensitive to light, regardless of its original function. Hegemann's research illuminated how certain microorganisms detect light through specialised proteins, while Nagel subsequently demonstrated that these proteins could operate as light-controlled ion channels.

Deisseroth then made the decisive leap into neuroscience. He introduced the gene for channelrhodopsin into rat nerve cells and, by shining blue light on them, triggered a nerve signal. He later demonstrated that this light-controlled switch could function inside the brains of living mice — giving rise to the field now known as optogenetics.

Why This Matters for Medicine

The implications extend well beyond the laboratory. Researchers using optogenetics have successfully mapped neural circuits that govern specific memories, feelings, and behaviours linked to neurological and psychiatric disorders such as depression, anxiety, and Parkinson's disease. In clinical applications, the method is being explored to restore sight in people with visual impairment, offering a potential therapeutic pathway for conditions once considered untreatable.

Who Are the Laureates

Karl Deisseroth is a professor of bioengineering, psychiatry, and behavioural sciences at Stanford University in the United States. Peter Hegemann is a German biophysicist whose career has focused on light-sensitive proteins in microorganisms. Georg Nagel is a German neuroscientist who contributed to the discovery and characterisation of microbial opsins and established their potential as light-controlled ion channels.

What Comes Next

The Nobel announcement marks a moment of global recognition for a field that has already reshaped how researchers approach brain disorders. With clinical trials testing optogenetics-based vision restoration ongoing in several countries, the prize is expected to accelerate funding and regulatory interest in translational neuroscience.